4//SEC Filing
Calkins Daniel 4
Accession 0001104659-25-051163
CIK 0001526119other
Filed
May 19, 8:00 PM ET
Accepted
May 20, 7:54 PM ET
Size
6.8 KB
Accession
0001104659-25-051163
Insider Transaction Report
Form 4
Verastem, Inc.VSTM
Calkins Daniel
Chief Financial Officer
Transactions
- Award
Common Stock
2025-05-16−38,850→ 125,198 total - Sale
Common Stock
2025-05-20$8.13/sh−11,143$90,593→ 114,055 total
Footnotes (2)
- [F1]The reported securities were subject to a performance RSU award that was granted on June 18, 2024. 150,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the FDA of an NDA for the Company's combination therapy of avutometinib and defactinib for the treatment of low-grade serous ovarian cancer had occurred.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
Documents
Issuer
Verastem, Inc.
CIK 0001526119
Entity typeother
Related Parties
1- filerCIK 0001951861
Filing Metadata
- Form type
- 4
- Filed
- May 19, 8:00 PM ET
- Accepted
- May 20, 7:54 PM ET
- Size
- 6.8 KB